ADAR1 Capital Management »

Design Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Design Therapeutics (DSGN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Design Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Design Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Design Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $29k 7.2k 4.03
2023-12-31 $5.3k 2.0k 2.65

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Design Therapeutics

Sr One Capital Management
Logos Global Management
BlackRock
BlackRock
Frazier Life Sciences Management
Baker Bros. Advisors
Point72 Asset Management
Tang Capital Management
Almitas Capital
Vanguard Group
Geode Capital Management
State Street Corporation
Goldman Sachs Group
Acadian Asset Management
D. E. Shaw & Co

View all funds holding Design Therapeutics